Sign in
Active, not recruitingPhase 3

Efficacy and Safety of Encaleret Compared to Standard of Care in Participants With ADH1

Key facts

Who runs it
Calcilytix Therapeutics, Inc., a BridgeBio company
Where
Aurora, Bethesda, Boston, Columbus, Greenville, Houston, Indianapolis, New York, Oakland, Philadelphia, and Rochester, United StatesSee the 11 sitesAlso in 9 other countries, 14 sites
Trial code
Status
Active, not recruiting
Phase
Phase 3
People taking part
67 people enrolled
Started
6 Jan 2023
Expected to end
Aug 2029
Type of study
Interventional, 2 groups
Treatments tested
  • Encaleret
  • Standard of Care
Record updated
29 July 2026

Who can take part

Age
16 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 16 criteriaShow less

Who can take part

  • Participants must have a documented pathogenic or likely pathogenic activating variant, or variant of uncertain significance, of the calcium sensing receptor (CASR) gene associated with biochemical findings of hypoparathyroidism
  • Participants must have a documented history of symptoms or signs of ADH1
  • Participants 16 to <18 years old must have closed growth plates on hand radiograph
  • Participants treated with thiazide diuretics must discontinue thiazides for at least 14 days prior to SoC Optimization Visit 1 through Week 24 (Period 3). When the thiazide is being used as an antihypertensive, alternative therapy will be prescribed by the Investigator as needed
  • Participants treated with phosphate binders (other than calcium salts) must discontinue the phosphate binders at least one day prior to the SoC Optimization Visit 1
  • Participants treated with magnesium or potassium supplements must be willing to discontinue such treatment prior to the first dose of encaleret
  • Participants treated with potassium-sparing diuretics must be willing to discontinue such treatment prior to the first dose of encaleret
  • Participants must meet SoC Optimization criteria as defined in the protocol

Who cannot take part

  • History of treatment with parathyroid hormone (PTH) 1-84 or 1-34 within the 2 months preceding Screening and requiring SoC doses exceeding >1.2× their pre-PTH treatment total daily doses or bone turnover markers, Collagen cross-linked C-telopeptide (CTx )and Procollagen type 1 N-propeptide (P1NP), > upper limit of normal for sex, age (men only) and menopausal status (women only)
  • History of hypocalcemic seizure within the past 3 months preceding Screening
  • History of thyroid or parathyroid surgery
  • History of renal transplantation
  • Participants with positive Hepatitis B surface antigen (HBsAg), Hepatitis A immunoglobulin M (IgM), or human immunodeficiency virus (HIV) viral serology test at the Screening Visit. Participants who are in complete remission from Hepatitis C virus (HCV) as evidenced by sensitive assay ≥12 weeks after completion of HCV therapy may participate in the study; Note: Other protocol defined Inclusion/Exclusion criteria may apply
  • Pregnant or nursing (lactating) women, where pregnancy is confirmed by a positive beta-human chorionic gonadotropin (β-hCG) laboratory test
  • Estimated glomerular filtration rate (eGFR) <30 mL/minute/1.73 m\^2 using chronic kidney disease-EPI creatinine equation refit without the race variable (chronic kidney disease-EPI creatinine equation refit without the race variable [CKD-EPIcr_R]) (for participants <18 years old the Bedside Schwartz equation should be used)
  • Blood 25-OH Vitamin D level <25 nanograms (ng)/milliliter (mL)

Where in United States

Also in 9 other countries, 14 sites

  • Children's Hospital ColoradoAurora, United States
  • NIHBethesda, United States
  • Massachusetts General HospitalBoston, United States
  • Ohio State University Medical CenterColumbus, United States
  • Physicians EastGreenville, United States
  • Houston Methodist HospitalHouston, United States
  • Indiana University Health University HospitalIndianapolis, United States
  • Columbia University Irving Medical CenterNew York, United States
  • UCSF Benioff Children's Hospital OaklandOakland, United States
  • The Children's Hospital Of PhiladelphiaPhiladelphia, United States
  • Mayo Clinic - RochesterRochester, United States

About the trial

What the trial wants to find out

The primary purpose of the study is to understand the effectiveness, safety, and tolerability of encaleret when compared to standard of care (SoC) treatment in participants with Autosomal Dominant Hypocalcemia Type 1 (ADH1).

The 2 groups in the trial

  • EncaleretTreatment being tested

    Participants will receive encaleret at a dose as needed based on calcium levels.

  • Standard of Care (SoC)Other group

    Participants will continue receiving calcium supplements and/or active Vitamin D (calcitriol, alfacalcidol, falecalcitriol, etc.)

    Treatment: Standard of Care

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
CALIBRATE: A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Encaleret Compared to Standard of Care in Participants With Autosomal Dominant Hypocalcemia Type 1 (ADH1)
Record updated
29 July 2026